InvestSMART

Acumentis Group Limited (ASX: ACU) - Announcements

- Current share price for ACU : $0.095

ASX company news and announcements for Acumentis Group Limited (ACU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acumentis Group Limited (ACU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acumentis Group Limited (ACU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Acumentis Group Limited (ACU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$21 Results of Pentrys trial 6 Jun 2006 2:21PM $0.090 $0.095 risen by 5.56%
$21 Trading Halt 6 Jun 2006 10:14AM $0.090 $0.095 risen by 5.56%
$21 Avantogen & Hawaii Biotech combine vaccine businesses 10 May 2006 8:53AM $0.110 $0.095 fallen by 13.64%
$21 Commitments Test Entity - Third Quarter Report 28 Apr 2006 7:32PM $0.110 $0.095 fallen by 13.64%
$21 Appendix 3B/Disclosure Document - Non-renounceable Issue 31 Mar 2006 10:10AM $0.124 $0.095 fallen by 23.33%
$21 A$5.7million fully underwritten non-renouceable rights issue 27 Mar 2006 10:01AM $0.110 $0.095 fallen by 13.32%
$21 Trading Halt 24 Mar 2006 10:21AM $0.114 $0.095 fallen by 16.96%
$21 Half Yearly Report & Half Year Accounts 16 Mar 2006 6:13PM $0.114 $0.095 fallen by 16.96%
$21 A$5.7 million capital raising 16 Mar 2006 10:01AM $0.124 $0.095 fallen by 23.33%
$21 Avantogen & Hawaii Biotech to Combine Vaccine Businesses 16 Mar 2006 9:22AM $0.124 $0.095 fallen by 23.33%
$21 Trading Halt 15 Mar 2006 11:09AM n/a $0.095 n/a
$21 ACU & Innovate merge key oncology program RP101 2 Feb 2006 9:04AM $0.157 $0.095 fallen by 39.57%
$21 Commitments Test Entity - Second Quarter Report 31 Jan 2006 7:57PM $0.119 $0.095 fallen by 20.24%
$21 Appendix 3B/Disclosure Document: Non-Renouceable Issue 3 Nov 2005 10:19AM $0.137 $0.095 fallen by 30.66%
$21 $5.7m fully underwritten Non-Renounceable Rights Issue 2 Nov 2005 11:55AM $0.132 $0.095 fallen by 28.19%
$21 Commitments Test Entity - First Quarter Report 31 Oct 2005 4:08PM $0.137 $0.095 fallen by 30.66%
$21 GPI-0100 Licensed for West Nile Virus &Dengue Fever Vaccines 12 Oct 2005 9:46AM $0.147 $0.095 fallen by 35.15%
$21 New test proves effective in more cancers 6 Oct 2005 10:14AM $0.151 $0.095 fallen by 37.17%
$21 Preliminary Final Report June 2005 13 Sep 2005 5:13PM $0.147 $0.095 fallen by 35.15%
$21 Reaches accord with Regalen Inc 6 Sep 2005 10:29AM $0.147 $0.095 fallen by 35.15%
$21 Response to ASX Query re Share Price 1 Sep 2005 9:54AM $0.132 $0.095 fallen by 28.19%
$21 Commitments Test Entity - Fourth Quarter Report 26 Jul 2005 5:31PM $0.175 $0.095 fallen by 45.65%
$21 Appoint Dr Reddy's to Manufacture it's Adjuvant to GMP Grade 23 Jun 2005 9:57AM $0.213 $0.095 fallen by 55.32%
$21 GPI-0100 receives European Patent 9 Jun 2005 10:15AM $0.222 $0.095 fallen by 57.23%
$21 To Co-Develop Genital Herpes Vaccine 7 Jun 2005 9:20AM $0.198 $0.095 fallen by 52.12%

551 - 575 of 601 results

Page 23 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.